Seres Therapeutics to Present at Two Upcoming May Conferences
- Deutsche Bank 43rd Annual Health Care Conference: The company will participate in 1x1 meetings on Wednesday, May 9 in Boston, Mass.
- Bank of America Merrill Lynch 2018 Health Care Conference: The company will present a corporate overview on Thursday, May 17 at 8:55 a.m. PT in Las Vegas, Nev.
A live audio webcast of the Bank of America Merrill Lynch presentation will be available under the “Investors and Media” section of Seres’ website. A replay will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications
Source: Seres Therapeutics, Inc.